Difference between revisions of "Lundbeck"
Josh Leeson (talk | contribs) |
Josh Leeson (talk | contribs) (→Lobbying firms) |
||
| Line 19: | Line 19: | ||
==Lobbying firms== | ==Lobbying firms== | ||
| − | *[[Munro and | + | *[[Munro and Forster]]<ref> [http://www.prca.org.uk/assets/files/Consultancy%20Register%20Sept-Nov%202014%20pdf(1).pdf Agency Register September to November 2014] ''PRCA'', accessed 27 January 2015 </ref> |
===2014=== | ===2014=== | ||
Revision as of 17:55, 28 January 2015
H. Lundbeck A/S (commonly known simply as Lundbeck) is a Danish international pharmaceutical company engaged in the research and development, production, marketing, and sale of drugs for the treatment of disorders in the central nervous system (CNS), including depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy and insomnia.[1]
Contents
People
Executive management
- Ulf Wiinberg - Chief Executive Officer
- Anders Gersel Pedersen - Executive Vice President
- Anders Götzsche - Executive Vice President, CFO
Board of Directors
- Håkan Björklund - Chairman, Remuneration Committee; Member, Audit Committee
- Christian Dyvig -Member, Remuneration & Scientific Committee
- Thorleif Krarup -Chairman, Audit Committee
- Melanie G. Lee - Member, Scientific Committee
- Jes Østergaard - Chairman, Scientific Committee
- Lars Rasmussen - Member, Audit & Remuneration Committee
- Mona Elisabeth Elster - Employee representative
- Jørn Mayntzhusen - Employee representative
- Kim Rosenville Christensen - Employee representative
Lobbying firms
2014
Drugs
Contact
- H. Lundbeck A/S
- Ottiliavej 9 2500 Valby Denmark
- Phone +45 3630 1311
- Fax: +45 3630 1940
- www.lundbeck.com
Notes
- ↑ About Us, Lundbeck.com.
- ↑ Agency Register September to November 2014 PRCA, accessed 27 January 2015
